866-997-4948(US-Canada Toll Free)

Coronary Stents-Medical Devices Pipeline Assessment, 2019

Published By :

GlobalData

Published Date : Dec 2019

Category :

Medical Equipments

No. of Pages : 409 Pages

Coronary Stents - Medical Devices Pipeline Assessment, 2019

Summary

GlobalData's Medical Devices sector report, Coronary Stents - Medical Devices Pipeline Assessment, 2019" provides an overview of Coronary Stents currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Coronary Stents pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Coronary Stents under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Coronary Stents and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Coronary Stents under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date
Table of Contents
1.1 List of Tables 9
1.2 List of Figures 22
2 Introduction 23
2.1 Coronary Stents Overview 23
3 Products under Development 24
3.1 Coronary Stents - Pipeline Products by Stage of Development 24
3.2 Coronary Stents - Pipeline Products by Segment 25
3.3 Coronary Stents - Pipeline Products by Territory 26
3.4 Coronary Stents - Pipeline Products by Regulatory Path 27
3.5 Coronary Stents - Pipeline Products by Estimated Approval Date 28
3.6 Coronary Stents - Ongoing Clinical Trials 29
4 Coronary Stents - Pipeline Products under Development by Companies 30
4.1 Coronary Stents Companies - Pipeline Products by Stage of Development 30
4.2 Coronary Stents - Pipeline Products by Stage of Development 34
5 Coronary Stents Companies and Product Overview 39
5.1 Aachen Resonance GmbH Company Overview 39
5.1.1 Aachen Resonance GmbH Pipeline Products & Ongoing Clinical Trials Overview 39
5.2 Abbott Vascular Inc Company Overview 40
5.2.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 40
5.3 Adcomp Technologies Inc. Company Overview 48
5.3.1 Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 48
5.4 Advanced Bifurcation Systems Inc Company Overview 49
5.4.1 Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 49
5.5 Aeon Bioscience Company Overview 51
5.5.1 Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview 51
5.6 AlviMedica Medical Technologies Inc Company Overview 52
5.6.1 AlviMedica Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 52
5.7 Amaranth Medical Inc Company Overview 63
5.7.1 Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 63
5.8 Arterius Ltd Company Overview 72
5.8.1 Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview 72
5.9 Atrium Medical Corp Company Overview 73
5.9.1 Atrium Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 73
5.10 Axordia Ltd (Inactive) Company Overview 74
5.10.1 Axordia Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 74
5.11 B. Braun Melsungen AG Company Overview 75
5.11.1 B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview 75
5.12 Bactiguard Holding AB Company Overview 76
5.12.1 Bactiguard Holding AB Pipeline Products & Ongoing Clinical Trials Overview 76
5.13 Bionext Biotech Products Ltd. Company Overview 77
5.13.1 Bionext Biotech Products Ltd. Pipeline Products & Ongoing Clinical Trials Overview 77
5.14 Biosensors International Group Ltd Company Overview 78
5.14.1 Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 78
5.15 Biosten, LLC Company Overview 85
5.15.1 Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview 85
5.16 Biotronik AG Company Overview 86
5.16.1 Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview 86
5.17 Biotronik SE & Co KG Company Overview 111
5.17.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 111
5.18 Boston Scientific Corp Company Overview 113
5.18.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 113
5.19 Cardionovum GmbH Company Overview 123
5.19.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 123
5.20 Cardiorev Pte Ltd (Inactive) Company Overview 127
5.20.1 Cardiorev Pte Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 127
6 Coronary Stents- Recent Developments 269
6.1 Nov 27, 2019: Indian stent-maker SMT acquires majority stake in Zarek 269
6.2 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019 269
6.3 Nov 14, 2019: Medtronic highlights leadership in inclusion, diversity, and equity in 2019 integrated performance report 272
6.4 Nov 13, 2019: Abbott announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020 273
6.5 Nov 12, 2019: Cook Medicals leadership updates in Asia-pacific reinforce focus on growth and physician relationships 274
7 Appendix 406
7.1 Methodology 406
7.2 About GlobalData 409
7.3 Contact Us 409
7.4 Disclaimer 409

List of Tables
Table 1: Coronary Stents - Pipeline Products by Stage of Development 24
Table 2: Coronary Stents - Pipeline Products by Segment 25
Table 3: Coronary Stents - Pipeline Products by Territory 26
Table 4: Coronary Stents - Pipeline Products by Regulatory Path 27
Table 5: Coronary Stents - Pipeline Products by Estimated Approval Date 28
Table 6: Coronary Stents - Ongoing Clinical Trials 29
Table 7: Coronary Stents Companies - Pipeline Products by Stage of Development 30
Table 8: Coronary Stents - Pipeline Products by Stage of Development 34
Table 9: Aachen Resonance GmbH Pipeline Products & Ongoing Clinical Trials Overview 39
Table 10: ARtax Coronary Stent - Product Status 39
Table 11: ARtax Coronary Stent - Product Description 39
Table 12: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 40
Table 13: Second Generation Bioresorbable Vascular Scaffold - Product Status 40
Table 14: Second Generation Bioresorbable Vascular Scaffold - Product Description 40
Table 15: Xience SBA Everolimus Eluting Coronary Stent System - Product Status 41
Table 16: Xience SBA Everolimus Eluting Coronary Stent System - Product Description 41
Table 17: XIENCE Thin man DES - Product Status 41
Table 18: XIENCE Thin man DES - Product Description 42
Table 19: ZoMaxx Drug Eluting Coronary Stent System - Product Status 42
Table 20: ZoMaxx Drug Eluting Coronary Stent System - Product Description 42
Table 21: Abbott Vascular Inc - Ongoing Clinical Trials Overview 43
Table 22: Xience SBA Everolimus Eluting Coronary Stent System - A Multi-center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries: CRYSTAL Study 44
Table 23: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective Global Randomized Trial Assessing the Safety and Efficacy of the BuMA Supreme Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients with Stable Coronary Artery Disease or Non-ST Segment Elevation Acute Coronary Syndromes 44
Table 24: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective Multicenter Randomized Post Market All-comer Trial to Assess the Safety and Effectiveness of the Supraflex Sirolimus-eluting Coronary Stent System for the Treatment of Atherosclerotic Lesion(s) 45
Table 25: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective, Open Label, Multi-center Trial of Firehawk Coronary Stent System in the Treatment of Coronary Chronic Total Artery Occlusion Lesion(S) by Optical Coherent Tomography (OCT) and Coronary Angiography 45
Table 26: Xience SBA Everolimus Eluting Coronary Stent System - A Safety Evaluation of 3-month Dual Antiplatelet Therapy in Subjects at High Risk of Bleeding Undergoing Percutaneous Coronary Intervention with XIENCE 45
Table 27: Xience SBA Everolimus Eluting Coronary Stent System - Polish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI) 46
Table 28: Xience SBA Everolimus Eluting Coronary Stent System - Short and Optimal Duration of Dual Antiplatelet Therapy-2 Study 46
Table 29: XIENCE Thin man DES - A Safety Evaluation of 3-month Dual Antiplatelet Therapy in Subjects at High Risk of Bleeding Undergoing Percutaneous Coronary Intervention with XIENCE 47
Table 30: Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 48
Table 31: Dual Drug Eluting Stent - Product Status 48
Table 32: Dual Drug Eluting Stent - Product Description 48
Table 33: Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 49
Table 34: Stenting System - Bare Metal Stent - Product Status 49
Table 35: Stenting System - Bare Metal Stent - Product Description 49
Table 36: Stenting System - Drug Eluting Stent - Product Status 50
Table 37: Stenting System - Drug Eluting Stent - Product Description 50
Table 38: Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview 51
Table 39: Drug Eluting Stent - Product Status 51
Table 40: Drug Eluting Stent - Product Description 51
Table 41: AlviMedica Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 52
Table 42: BMS - Avantgarde - Product Status 52
Table 43: BMS - Avantgarde - Product Description 53
Table 44: Commander - Product Status 53
Table 45: Commander - Product Description 53
Table 46: Cre8 DES - Product Status 54
Table 47: Cre8 DES - Product Description 54
Table 48: Cre8 EVO DES - Product Status 54
Table 49: Cre8 EVO DES - Product Description 55
Table 50: DES - Coracto - Product Status 55
Table 51: DES - Coracto - Product Description 55
Table 52: Ephesos II - Product Status 56
Table 53: Ephesos II - Product Description 56
Table 54: Inperia Advance - Product Status 56
Table 55: Inperia Advance - Product Description 57
Table 56: AlviMedica Medical Technologies Inc - Ongoing Clinical Trials Overview 58
Table 57: Cre8 DES - A Prospective, Multi-center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8 59
Table 58: Cre8 DES - A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent Versus the RESOLUTE Zotarolimus-eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions 59
Table 59: Cre8 DES - A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of CRE8 Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions 60

List of Figures
Figure 1: Coronary Stents - Pipeline Products by Stage of Development 24
Figure 2: Coronary Stents - Pipeline Products by Segment 25
Figure 3: Coronary Stents - Pipeline Products by Territory 26
Figure 4: Coronary Stents - Pipeline Products by Regulatory Path 27
Figure 5: Coronary Stents - Pipeline Products by Estimated Approval Date 28
Figure 6: Coronary Stents - Ongoing Clinical Trials 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *